Vitamin D Courses: What the Evidence Actually Supports, and for Whom

French dermatologists and endocrinologists agree on one seasonal fact: from October to March, UVB rays at French latitudes are too weak to trigger meaningful vitamin D synthesis in skin. That has fueled a familiar autumn ritual, the vitamin D "cure," often taken without a blood test or a clear sense of who actually needs it.

The evidence for that ritual is thinner than the habit suggests. The Endocrine Society's 2024 clinical practice guideline, developed by a panel led by endocrinologist Marie Demay of Massachusetts General Hospital, advises against routine vitamin D testing or supplementation in healthy adults under 75 who are not pregnant. The panel found insufficient evidence that supplementation prevents disease in this general population, and recommended reserving empiric doses for specific groups instead: adults 75 and older, pregnant women, people with prediabetes, and children and adolescents aged one to eighteen.

That distinction matters because the outcome researchers most often invoke to justify supplementation, fracture prevention, has not held up in the largest trial designed to test it. The VITAL trial, led by JoAnn Manson at Brigham and Women's Hospital and published in the New England Journal of Medicine in 2022, followed nearly 26,000 generally healthy American adults over roughly five years. Daily doses of 2,000 IU of vitamin D3 produced no significant reduction in total fractures compared with placebo, even though earlier observational studies had linked low vitamin D levels to fragility fractures.

The gap between observational associations and trial results is why grading the evidence matters. Low vitamin D levels correlate with worse bone density, weaker muscle function and higher fall risk in cohort studies, but correlation studies cannot separate cause from consequence: people who are already frail, housebound or ill tend to have lower vitamin D and worse outcomes for reasons that supplementation alone may not fix.

In practice, the people for whom a course of vitamin D has the clearest backing are narrower than marketing implies. Institutional guidance points to adults over 70 or 75, whose skin synthesizes vitamin D less efficiently and who are more likely to spend winter indoors, plus people with darker skin tone, malabsorption conditions such as Crohn's disease or celiac disease, obesity, or limited sun exposure for cultural or occupational reasons. Pregnant women are included because of documented links between severe deficiency and complications affecting the fetus.

For those groups, the timing question has a defensible answer: a single course covering the low-sun months, typically one dose or a short daily regimen started in October or November and continued through March, mirrors the period when cutaneous synthesis is minimal. Some clinicians favor one large bolus dose (100,000 IU) every three months over daily lower doses, though the Endocrine Society panel found no clear evidence one schedule outperforms the other for the outcomes it reviewed, weight, cardiovascular disease or cancer among them.

What the panel did flag as a real risk is excess: because vitamin D is fat soluble and accumulates in tissue, repeated high-dose courses taken without medical supervision can push blood calcium into toxic ranges, producing symptoms from nausea to kidney stones. That risk, more than the seasonal UVB chart that starts every autumn conversation about vitamin D, is the detail worth checking with a doctor before opening a new box.